Algorithm-Designed Antimicrobial Peptides for MRSA and MDRAB
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides face challenges in effectively targeting a wide spectrum of microorganisms, including drug-resistant bacteria, and often fail to balance efficacy with safety, particularly in maintaining activity against Gram-positive and Gram-negative bacteria while minimizing toxicity to mammalian cells.
Innovation Solution
Development of novel antimicrobial peptides with specific amino acid sequences (SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3) designed using algorithm-aided methods, which are synthesized and tested for their bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDRAB), with formulations for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then they can effectively kill bacteria, but drug-resistant bacteria develop leading to treatment failure
Solution Approach 1:
The patent employs algorithm-aided design to optimize peptide parameters including amino acid composition, charge distribution, and hydrophobicity patterns. This systematic parameter optimization enables the peptides to effectively target both Gram-positive and Gram-negative bacteria while maintaining low toxicity, resolving the contradiction between efficacy and broad-spectrum activity.
Solution Approach 2:
The invention creates composite antimicrobial peptides that integrate multiple functional elements: cationic amino acids for electrostatic interaction with bacterial membranes, hydrophobic regions for membrane insertion, and amphipathic structures for conformational flexibility. This composite design achieves broad-spectrum activity against diverse microorganisms including drug-resistant strains.
2Reliability
If antimicrobial peptides are designed with high efficacy against a wide spectrum of microorganisms, then they can treat drug-resistant bacteria, but it becomes difficult to maintain safety and minimize toxicity to mammalian cells
Solution Approach 1:
The patent applies local quality optimization by designing peptides with spatially differentiated properties: cationic residues concentrated at specific positions for electrostatic attraction to negatively charged bacterial surfaces, hydrophobic patches positioned for selective membrane insertion, and amphipathic regions oriented to favor bacterial over mammalian cell interaction. This localized functional differentiation achieves high antimicrobial efficacy while minimizing mammalian cell toxicity.
Solution Approach 2:
The algorithm-aided design systematically optimizes critical parameters including net charge density, hydrophobic moment, and amphipathic index to enhance selective toxicity. By precisely tuning these parameters, the peptides achieve optimal balance between killing bacteria and sparing mammalian cells, resolving the efficacy-safety contradiction.
3Adaptability or versatility
If antimicrobial peptides are designed based on algorithm methods with specific physical properties, then they can achieve broad-spectrum activity, but only a few peptides could be designed effectively while maintaining safety and efficacy
Solution Approach 1:
The patent implements preliminary action through algorithm-aided design that pre-calculates optimal peptide sequences based on desired physical properties and target microorganism characteristics. This preliminary computational design filters and prioritizes candidate peptides before synthesis and testing, dramatically improving design efficiency and enabling systematic development of broad-spectrum antimicrobial peptides with controlled safety profiles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate potent bactericidal activity with IC50 values below 0.2 μM and MBC values below 1.56 μM against target bacteria, while showing minimal hemolysis and cytotoxicity, making them promising candidates for broad-spectrum antimicrobial agents.
Implementation Method 1
the electrostatic interaction between the positively charged amino acids in the peptides and the negatively charged teichoic acid or peptidoglycan in the membrane of the bacteria
Implementation Method 2
the hydrophobic interaction that contributes to the conformational change in the peptides
Data Source
AI summary
The present invention relates to novel antimicrobial peptides and compositions comprising the same. The present invention also provides a method for for treating microbial infections, including bacterial infections and fungal infections.